Overexpression of Cyclooxygenase-2 in Carcinoma of the Pancreas

Jiro Okami, Hirofumi Yamamoto, Yoshiyuki Fujiwara, Masaki Tsujie, Motoi Kondo, Shingo Noura, Satoshi Oshima, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Osamu Ishikawa, Masato Sakon, Nariaki Matsuura, Shoji Nakamori,2 and Morito Monden

Department of Surgery II, Osaka University Medical School, Osaka 565-0871, Japan [J. O., H. Y., Y. F., M. T., M. K., S. N., S. O., H. N., K. D., K. U., M. S., S. Na., M. M.]; Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka 537-8511, Japan [O. I.]; and Department of Pathology, School of Allied Health Science, Faculty of Medicine, Osaka University, Osaka 565-0871, Japan [N. M.]

ABSTRACT

The level of cyclooxygenase (COX)-2 has been investigated recently in various human carcinomas. In the present study, we examined the distribution and extent of COX-2 protein in human pancreatic tumors using immunohistochemistry. A strong expression of COX-2 protein was present in 23 of 52 (44%) pancreatic carcinomas, a moderate expression was present in 24 of 52 (46%) pancreatic carcinomas, and a weak expression was present in 5 of 52 (10%) pancreatic carcinomas. In contrast, benign tumors showed weak expression or no expression of COX-2, and only islet cells displayed COX-2 expression in normal pancreatic tissues. Overexpression of COX-2 in carcinoma tissues was also confirmed by Western blot analysis. Furthermore, consistent with the results at protein levels, reverse transcription-PCR analyses indicated that COX-2 mRNA was overexpressed in 7 of 13 (54%) carcinomas, but in none of 3 benign tumors. Our findings suggest that COX-2 inhibitors might be potentially effective against pancreatic carcinomas and that COX-2 may be involved in certain biological processes in pancreatic islets.

INTRODUCTION

The incidence of carcinoma of the pancreas is associated with a high mortality rate. In the United States, the 5-year overall survival has increased from 1% in 1961 to only 3–5% in 1991. The annual incidence in Western societies is nearly 10 per 100,000 total population (1). The incidence in most developed countries is similar to that of the United States, particularly among urban and socioeconomically disadvantaged populations. Several factors have been implicated for the recent rise in the frequency of pancreatic carcinoma, including cigarette smoking, gallstones, a diet high in animal fat, and chronic calcific pancreatitis (2). Although few studies have suggested the possible role of K-ras oncogenes, tumor suppressor genes (p16, p53, and DPC4), and growth factors (epidermal growth factor, basic fibroblast growth factor, and insulin-like growth factor I) in carcinoma of the pancreas, the exact pathogenic mechanisms and progression of this neoplasm remain to be clarified, and no effective strategy for treatment of this disease has been established thus far (3–7).

COX3 is a rate-limiting enzyme involved in the conversion of arachidonic acid to prostaglandin H2, the precursor of several molecules including prostaglandins, prostacyclin, and thromboxanes. Two COX genes, COX-1 and COX-2, have been identified that share a >60% identity at the amino acid level (8). COX-1 is constitutively expressed in many tissues and is responsible for various physiological functions including the cytoprotection of the stomach, vasodilatation in the kidney, and the production of a proaggregatory prostanoid, thromboxane, by the platelets. On the other hand, COX-2 is an inducible immediate early gene and was originally found to be induced by inflammation and ovulation or by a variety of other stimuli, such as mitogens, cytokines, and growth factors (9–11). Overexpression of COX-2 has been demonstrated in human inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and Helicobacter pylori-infectious gastritis (12–14).

Recent studies have highlighted the potential role of COX-2 in carcinogenesis. In 1994, the induction of COX-2 was reported in carcinomas of the colon, and in subsequent years, increased levels of COX-2 were found in carcinomas of the stomach, breast, esophagus, and lung (15–21). In contrast, the levels of COX-1 are mostly similar between normal and tumor tissues. Importantly, overexpression of COX-2 in human carcinomas appears to be of functional significance because double knockout mice for adenomatous polyposis coli and COX-2 genes showed a reduction in the size and frequency of intestinal polyps (22). There is also cumulative evidence that selective COX-2 inhibitors prevent carcinogenesis in experimental animals (23) and that these compounds induce apoptosis in several types of carcinoma cells (24). These findings suggest that COX-2 may be associated with carcinogenesis and/or the progression of certain types of human malignancies. In fact, various

---

2 To whom requests for reprints should be addressed, at Department of Surgery II, Osaka University Medical School, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan.
3 The abbreviations used are: COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug; PBGD, porphobilinogen deaminase; RT-PCR, reverse transcription-PCR; T:N, tumor:normal.
stained sections were coded and evaluated without prior knowledge. Excess amounts of preabsorbed antibody with an excess amount of immunogen abolished the staining. Staining was repeated twice to rule out nonspecific binding to IgG or the secondary antibody. In addition, to minimize possible inter-PCR differences, PCR was performed in a 25-μl reaction mixture containing 1 μl of cDNA template, 1× Perkin-Elmer PCR buffer, 1.5 mM MgCl₂, 0.8 mM deoxyribonucleotide triphosphates, 0.8 μM of each primer for COX-2 or 80 nM of each primer for COX-1, and 80 nM PBGD, and 1 unit of Taq DNA polymerase (AmpliTaq Gold; Roche Molecular Systems, Inc.). The PCR primers used for detection of COX-1, COX-2, and PBGD cDNAs were synthesized as described previously, and amplified products were 303, 305, and 127 bp, respectively (35, 36). The conditions for multiplex PCR were one cycle of denaturing at 95°C for 12 min, followed by 40 cycles of 95°C for 1 min, 62°C for 1 min, and 72°C for 1 min, and a final extension at 72°C for 10 min. The electrophoresed PCR products were scanned by densitometry, and the relative value of the COX-2 or COX-1 band as compared to the PBGD band was calculated in each sample.

Western Blot Analysis. Western blot analysis was performed as described previously (37). Briefly, 100 μg of the total protein from tissues and 2.5 μg/ml COX-2 antibody were used for this assay.

Statistical Analysis. Statistical analysis was performed using the Statview J software (version 4.5). The χ² and Fisher’s exact tests were used to examine the association between COX-2 expression and clinicopathological parameters. P < 0.05 denoted the presence of a statistically significant difference.

RESULTS

Immunohistochemistry

COX-2 Expression in Normal Pancreatic Tissues. Only normal pancreatic tissues without significant inflammation were examined. COX-2 expression was not detected in epithe-
lial cells of normal pancreatic ducts or in normal acinar cells. In contrast, pancreatic islets exclusively displayed a strong expression of COX-2 (Fig. 1A).

**COX-2 Expression in Pancreatic Tumors.** Four benign tumors (cystadenomas) and 52 carcinomas (48 adenocarcinomas and 4 adenosquamous carcinomas) were examined. In benign tumor specimens, a weak COX-2 staining or no COX-2 staining was detected (Fig. 1B; Table 1). In contrast, a moderate to strong expression of COX-2 was noted in most carcinomas. Specifically, a strong expression of COX-2 protein was present in 23 of 52 (44%) pancreatic carcinomas, moderate expression was present in 24 of 52 (46%) pancreatic carcinomas, and weak expression was present in 5 of 52 (10%) pancreatic carcinomas. The level of COX-2 expression in benign tumors was significantly different from that in malignant tumors (Table 1; \(P < 0.05\)).

When COX-2 expression was analyzed according to the histology of pancreatic carcinoma, we found that moderate to strong expression of this enzyme was detected in most cases, irrespective of histological type or grade (Fig. 1, C–E; Table 2). We also determined the percentage of COX-2-positive cells because several carcinomas displayed a heterogeneous expression of COX-2, as described in “Materials and Methods.” The results of this analysis are summarized in Table 2.

To confirm the specificity of COX-2 antibody staining, we

---

**Fig. 1** Immunostaining for COX-2 in pancreatic tissues. A, normal pancreatic tissue. Islets cells display a strong staining, whereas epithelial cells of the pancreatic duct (arrow) or acinar cells are negative for COX-2. B, pancreatic serous cystadenoma. Note the weakly positive staining for COX-2 in adenoma cells of the cyst wall. C, intraductal papillary adenocarcinoma. D, well-differentiated adenocarcinoma. E, poorly differentiated adenocarcinoma. Magnification, \( \times 50 \) (A–E).
examined the expression of COX-2 in three sets of paired normal and carcinoma tissues by Western blot analysis using a recombinant COX-2 protein as a positive control. COX-2 protein was clearly expressed by carcinoma tissues, but normal pancreatic tissues expressed scarce bands (data not shown). In addition, preabsorbed antibody with an excess amount of the immunogens eliminated the band corresponding to COX-2 (data not shown), indicating that the antibody was specific for COX-2.

We then determined the immunoreactive score for each individual carcinoma case by multiplying the percentage of positive cells by the staining intensity, as reported previously (38, 39). The immunoreactive score ranged from 10–300, with positive cells by the staining intensity, as reported previously (38, 39). The immunoreactive score ranged from 10–300, with an average value of 180. Based on this analysis, patients with malignant carcinoma case by multiplying the percentage of positive cells by the staining intensity, as reported previously (38, 39). The immunoreactive score ranged from 10–300, with positive cells by the staining intensity, as reported previously (38, 39). The immunoreactive score ranged from 10–300, with an average value of 180. Based on this analysis, patients with malignant tumors were classified into two groups: (a) 27 high expressers; and (b) 25 low expressers, using a cutoff value equivalent to the above median value. Using this classification, we did not find any significant difference between the two groups based on various clinicopathological parameters, such as age, sex, histological grade, tumor size, nodal involvement, metastasis, stage (UICC, the International Union Against Cancer, classification), and site of the tumor (Table 2).

**RT-PCR**

To examine the level of mRNA for COX-2, a RT-PCR assay was performed using the BxPC3, FCI6, and PSN1 pancreatic carcinoma cell lines and 16 paired nontumor and tumor tissues (13 malignant tumors and 3 benign tumors). Each of the three carcinoma cell lines expressed a 305-bp band for COX-2 and a 303-bp band for COX-1, with constitutive expression of PBGD (Fig. 2, top and bottom panels). To estimate the expression of COX-2 in tumor tissues relative to that in the matched normal tissues, we calculated the T:N ratio representing the expression of COX-2 in the tumor (COX-2/PBGD) relative to that in normal tissue (COX-2/PBGD). In the three benign samples, the COX-2 T:N ratio was 1.00, 0.43, and 0.39. In 13 carcinoma samples, the value ranged from 0.46–37.0 (<1.0, two cases; 1.0–2.0, four cases; and >2.0, seven cases). When overexpression of COX-2 mRNA was defined as a T:N ratio of >2.0, COX-2 mRNA was overexpressed in 7 of 13 (54%) carcinoma cases. There was no significant difference in the level of COX-1 mRNA between normal and tumor tissues, in benign tumors as well as malignant tumors (Fig. 2, bottom panel). These assays were repeated at least twice, and concordant results were obtained.

**DISCUSSION**

Epidemiological studies indicate that the administration of NSAIDs results in a marked reduction in adenoma size and number and not infrequently leads to a complete regression of colonic polyps in patients with familial adenomatous polyposis (40–42). NSAIDs also reduce the risk of sporadic colorectal, breast, and lung cancers (43, 44). These effects of NSAIDs on the inhibition of carcinogenesis have also been demonstrated in animal experiments, including a pancreatic neoplasm in N-nitrosobis(2-oxopropyl)amine-treated hamsters (45). Several lines of evidence indicate that the antitumor effects of NSAIDs may be due in part to the inhibition of COX-2 activity (22, 46–48). Indeed, in carcinomas of the colon and lung and also in gastric and esophageal carcinomas, the level of COX-2 expression is significantly increased. These findings suggest that up-regulation of this enzyme might be a common mechanism for carcinogenesis of cells of an epithelial origin. Pancreatic carcinoma is one of the most stressful diseases for patients and physicians, and most pancreatic carcinomas (approximately 90–95%) are ductal adenocarcinomas derived from epithelial cells of the pancreatic ducts. The present study was performed to investigate the involvement of COX-2 in a variety of pancreatic tumors.

In pancreatic carcinoma tissues, the cellularity of the carcinoma cells was relatively low (approximately 10–50%), but we still found that COX-2 expression was increased at both the RNA and protein levels in most of the pancreatic carcinomas.
Overexpression of COX-2 in Pancreatic Cancer

Previous studies have shown a low basal level of COX-2 mRNA in normal pancreatic tissues (36). Consistent with this finding, the present data indicated that COX-2 protein was localized exclusively to islets that occupied a minimal area of the normal pancreas, but not in epithelial cells of the duct or in acinar cells. Our immunohistochemical data on COX-2 expression in the islets are consistent with recent reports from other laboratories (53, 54), and islet cells served well as internal controls for COX-2 staining in a series of sections. The significance of COX-2 expression in the islets is unclear at present. Experiments using COX-2 inhibitors may allow a better understanding of the possible role of COX-2 in pancreatic islet physiology and the pathogenesis of diabetes mellitus because prostaglandin E2 negatively regulates pancreatic islet function, i.e., glucose-induced insulin secretion. During the observation of COX-2 staining in carcinomatous tissues, we found that islet cells always showed a high expression of COX-2, even when acinar cells changed into fibrous tissues. This finding is of potential importance with regard to the association of COX-2 with carcinogenesis because we have previously demonstrated that the transplantation of pancreatic islets to the submandibular glands led to carcinoma formation in N-nitrosobis(2-oxopropyl)amine-treated hamsters (55).

In conclusion, we report overexpression of COX-2 in various histological types of pancreatic carcinomas. Our data suggest that COX-2 inhibitors might be potentially effective against the development and/or progression of human pancreatic carcinoma.

ACKNOWLEDGMENTS

We thank Dr. H. Ishikura for the generous supply of human pancreatic carcinoma cell line PCI6.

REFERENCES


Downloaded from clincancerres.aacrjournals.org on July 15, 2017. © 1999 American Association for Cancer Research.


Overexpression of Cyclooxygenase-2 in Carcinoma of the Pancreas


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/5/8/2018

Cited articles
This article cites 53 articles, 25 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/5/8/2018.full#ref-list-1

Citing articles
This article has been cited by 24 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/5/8/2018.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.